112 related articles for article (PubMed ID: 25174742)
1. [Specific degradation of nuclear hepatitis B virus covalently closed circular DNA].
Lucifora J; Xia Y; Reisinger F; Stadler D; Heikenwälder M; Protzer U
Med Sci (Paris); 2014; 30(8-9):724-6. PubMed ID: 25174742
[No Abstract] [Full Text] [Related]
2. G1 phase dependent nuclear localization of relaxed-circular hepatitis B virus DNA and aphidicolin-induced accumulation of covalently closed circular DNA.
Yeh CT; Chiu HT; Chu CM; Liaw YF
J Med Virol; 1998 May; 55(1):42-50. PubMed ID: 9580885
[TBL] [Abstract][Full Text] [Related]
3. Virology. Response to Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA".
Xia Y; Lucifora J; Reisinger F; Heikenwalder M; Protzer U
Science; 2014 Jun; 344(6189):1237. PubMed ID: 24926011
[TBL] [Abstract][Full Text] [Related]
4. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.
Lucifora J; Xia Y; Reisinger F; Zhang K; Stadler D; Cheng X; Sprinzl MF; Koppensteiner H; Makowska Z; Volz T; Remouchamps C; Chou WM; Thasler WE; Hüser N; Durantel D; Liang TJ; Münk C; Heim MH; Browning JL; Dejardin E; Dandri M; Schindler M; Heikenwalder M; Protzer U
Science; 2014 Mar; 343(6176):1221-8. PubMed ID: 24557838
[TBL] [Abstract][Full Text] [Related]
5. Virology. Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA".
Chisari FV; Mason WS; Seeger C
Science; 2014 Jun; 344(6189):1237. PubMed ID: 24926010
[TBL] [Abstract][Full Text] [Related]
6. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.
Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA.
Ahmed M; Wang F; Levin A; Le C; Eltayebi Y; Houghton M; Tyrrell L; Barakat K
Drug Discov Today; 2015 May; 20(5):548-61. PubMed ID: 25622780
[TBL] [Abstract][Full Text] [Related]
8. Cytidine deamination and cccDNA degradation: A new approach for curing HBV?
Ding S; Robek MD
Hepatology; 2014 Dec; 60(6):2118-21. PubMed ID: 25142126
[No Abstract] [Full Text] [Related]
9. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation.
Wei ZQ; Zhang YH; Ke CZ; Chen HX; Ren P; He YL; Hu P; Ma DQ; Luo J; Meng ZJ
World J Gastroenterol; 2017 Sep; 23(34):6252-6260. PubMed ID: 28974891
[TBL] [Abstract][Full Text] [Related]
10. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
11. Virology. Getting rid of a persistent troublemaker to cure hepatitis.
Shlomai A; Rice CM
Science; 2014 Mar; 343(6176):1212-3. PubMed ID: 24626921
[No Abstract] [Full Text] [Related]
12. Promyelocytic leukemia nuclear bodies link the DNA damage repair pathway with hepatitis B virus replication: implications for hepatitis B virus exacerbation during chemotherapy and radiotherapy.
Chung YL; Tsai TY
Mol Cancer Res; 2009 Oct; 7(10):1672-85. PubMed ID: 19808906
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
14. TGF-β triggers HBV cccDNA degradation through AID-dependent deamination.
Qiao Y; Han X; Guan G; Wu N; Sun J; Pak V; Liang G
FEBS Lett; 2016 Feb; 590(3):419-27. PubMed ID: 26867650
[TBL] [Abstract][Full Text] [Related]
15. Control of cccDNA function in hepatitis B virus infection.
Levrero M; Pollicino T; Petersen J; Belloni L; Raimondo G; Dandri M
J Hepatol; 2009 Sep; 51(3):581-92. PubMed ID: 19616338
[TBL] [Abstract][Full Text] [Related]
16. Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays.
Wu M; Li J; Yue L; Bai L; Li Y; Chen J; Zhang X; Yuan Z
Antiviral Res; 2018 Apr; 152():45-52. PubMed ID: 29432776
[TBL] [Abstract][Full Text] [Related]
17. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
Revill P; Locarnini S
Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation.
Guo H; Jiang D; Zhou T; Cuconati A; Block TM; Guo JT
J Virol; 2007 Nov; 81(22):12472-84. PubMed ID: 17804499
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapeutics and relevant targets for chronic Hepatitis B.
Song IH
Turk J Gastroenterol; 2016 May; 27(3):210-5. PubMed ID: 27210776
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
